Cellectricon
Cellectricon is a Swedish life sciences services company that provides cell-based screening and neurotoxicity testing to pharmaceutical and biotech drug developers, using validated in vitro models with optical electrophysiology, high-content imaging, and microfluidic assay systems.
- Company typePrivate
- Founded2001
- HeadquartersMölndal, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cellectricon does
Cellectricon is a Swedish life sciences services company founded in 2001 and headquartered in Mölndal, Sweden. The company provides advanced cell-based screening services that support pharmaceutical drug discovery, with a specialization in neuroscience and neurotoxicity assessment. Its core offering is the Neuroscience Discovery Platform, which combines validated in vitro models with three advanced assay technologies: optical electrophysiology assays that read neural activity through optical methods, high-content imaging for comprehensive cellular and neural response analysis, and microfluidic lab-on-a-chip systems that enable controlled environments for acute and chronic neurotoxicity endpoint evaluation. In November 2025, Cellectricon launched dedicated Neurotoxicity Testing Services as an extension of this platform to address early-stage safety assessment of drug candidates.
The company serves pharmaceutical and biotechnology drug developers through a B2B professional services model, with a current strategic focus on developers of oligonucleotide-based therapeutics, a growing drug class whose unique mechanisms require specialized neurotoxicity evaluation. Revenue is generated through individually negotiated service contracts for custom in vitro testing engagements, with pricing quoted on a per-engagement basis rather than through published rate cards. The go-to-market is direct enterprise sales targeting pharma and biotech decision-makers, consistent with the specialized, high-touch nature of contracted laboratory services.
Cellectricon operates with a small team of 11-50 employees and has historically been lightly funded, with its last disclosed institutional round closing in 2004 (approximately $7M led by Investor Growth Capital and Karolinska, on top of two prior rounds totaling roughly $6.8M). Leadership is held by CEO Mattias Karlsson and COO Johan Pihl. The company has no disclosed app product, API, public-company listing, or active M&A activity based on the available data.
Cellectricon firmographics
Firmographics- Name
- Cellectricon
- Website
- https://cellectricon.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cellectricon is a Swedish life sciences services company that provides cell-based screening and neurotoxicity testing to pharmaceutical and biotech drug developers, using validated in vitro models with optical electrophysiology, high-content imaging, and microfluidic assay systems.
- Ownership category
- akta.pro rank
Cellectricon industry classification
Industry- Product category
- Preclinical Contract Research Organization (CRO) Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
- akta.pro secondary industries
- Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology) (HLAIALAC), Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB)
Keywords
Where Cellectricon is headquartered
LocationHeadquarters
- HQ city
- Mölndal
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Cellectricon business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Neurotoxicity Testing Services: Contracted testing services provided to pharmaceutical and biotech companies for early-stage safety assessment of drug candidates. Revenue is generated through service contracts for in vitro neurotoxicity testing using the company's validated models and advanced assay technologies.
Go-to-market motion1 record
Distribution channels1 record
Cellectricon product offering
Product offeringCore offering
Cellectricon provides advanced cell-based in vitro neurotoxicity testing services for pharmaceutical and biotech drug developers. Using validated human-relevant neural models combined with optical electrophysiology, high-content imaging, and microfluidic assay systems, the company evaluates acute and chronic neurotoxicity endpoints in drug candidates during preclinical development. The service is particularly positioned for developers of oligonucleotide-based therapeutics who require specialized early-stage safety assessment.
Product overview
Cellectricon offers a neuroscience discovery platform as its core offering, augmented by specialized testing services. The platform provides drug discovery and safety assessment services, with the Neurotoxicity Testing Services representing a new module that expands the platform's early safety assessment capabilities. The services utilize in vitro models with advanced assay technologies including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate neurotoxicity endpoints.
Differentiator
Problem solved
Functional benefit
Products and services
- Neurotoxicity Testing Services In vitro neurotoxicity testing services that leverage validated models with advanced assays including optical electrophysiology, high-content imaging, and microfluidic systems to evaluate acute and chronic neurotoxicity endpoints of drug candidates. Aimed at pharmaceutical and biotech developers, particularly those working on oligonucleotide-based therapeutics.
- Neuroscience Discovery Platform Cellectricon's core platform providing neuroscience research and cell-based screening services for drug discovery, now expanded to include neurotoxicity testing capabilities for early safety assessment of drug candidates.
Companies that use Cellectricon
Customer profileSegments1 record
Ideal customer profiles1 record
Cellectricon technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cellectricon partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Cellectricon competitors and assessment
Company assessmentDirect peers
- Reaction Biology Corporation: Preclinical services provider offering in vitro pharmacology, DMPK, and safety assays. Comparable as a contract research services firm serving pharma and biotech discovery and safety workflows.
- Neuroservice: Specialized CRO focused on electrophysiology and in vitro neuroscience assays for drug discovery. Directly comparable as a niche electrophysiology services provider competing in the same neurotoxicology testing space.
- Inotiv: Preclinical CRO providing toxicology, safety pharmacology, and research models. Comparable as a direct competitor in contract preclinical safety and neurotoxicity testing services.
- Metrion Biosciences: Specialist ion channel and neuroscience CRO offering electrophysiology and in vitro safety assays. Closely comparable as a niche preclinical services provider with overlapping electrophysiology-based neurotoxicology capabilities.
- Evotec (incl. Cyprotex): Provides preclinical in vitro ADME, toxicology, and safety pharmacology services through Cyprotex. Closely comparable as a specialized in vitro toxicology services provider supporting drug discovery safety assessment.
Broad incumbents
- Charles River Laboratories: Global preclinical CRO offering extensive safety assessment, neurotoxicology, and in vitro services. Directly comparable as a scaled incumbent competing for the same outsourced neurotoxicity testing budgets.
- Bio-Techne: Life sciences tools and services company offering reagents, assays, and contract services including neuroscience applications. Comparable as an established player providing both enabling tools and adjacent services to neuroscience drug discovery.
- WuXi AppTec: Large global CRO/CDMO offering preclinical toxicology and safety assessment services. Comparable as a scaled alternative for pharmaceutical customers seeking outsourced neurotoxicology testing.
- Eurofins Discovery: Part of Eurofins Scientific, offering drug discovery, in vitro pharmacology, and safety screening services. Comparable as a broad life-sciences services provider with overlapping in vitro neuroscience and toxicology capabilities.
- Pharmaron: Global CRO offering in vitro and in vivo preclinical services including safety assessment. Comparable as a broad preclinical services competitor for outsourced neurotoxicology testing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Cellectricon social profiles
Digital presenceCellectricon financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellectricon leadership team
Management profileNumber of profiles
Profiles2 records
Cellectricon funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellectricon M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellectricon
What does Cellectricon do?
Cellectricon provides advanced cell-based in vitro neurotoxicity testing services for pharmaceutical and biotech drug developers. Using validated human-relevant neural models combined with optical electrophysiology, high-content imaging, and microfluidic assay systems, the company evaluates acute and chronic neurotoxicity endpoints in drug candidates during preclinical development. The service is particularly positioned for developers of oligonucleotide-based therapeutics who require specialized early-stage safety assessment.
Is Cellectricon a public or private company?
Cellectricon is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellectricon founded?
Cellectricon was founded in 2001. It employs 11 to 50 people.
Where is Cellectricon based?
Cellectricon is headquartered in Mölndal, Sweden, in the Europe region.
How does Cellectricon make money?
One revenue line is on record: neurotoxicity Testing Services.
Who are Cellectricon's main competitors?
Direct peers on record are Reaction Biology Corporation, Neuroservice, Inotiv, Metrion Biosciences and Evotec (incl. Cyprotex). Broad incumbents are Charles River Laboratories, Bio-Techne, WuXi AppTec, Eurofins Discovery and Pharmaron.
Does Cellectricon have an API?
No public API is recorded for Cellectricon.
What industry is Cellectricon in?
Cellectricon's product category is Preclinical Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 541714 and its SIC code is 8734.